Introduction
Claudin18.2 CAR-T cell therapy is one of the most promising advances in the field of cellular immunotherapy for solid tumors. It is designed to target Claudin18.2 (CLDN18.2), a protein that is highly expressed in several gastrointestinal cancers while showing limited expression in normal tissues. This selective expression makes Claudin18.2 an attractive target for precision cancer treatment.
Unlike conventional therapies such as chemotherapy and radiation, Claudin18.2 CAR-T therapy utilizes genetically engineered immune cells to recognize and attack cancer cells expressing the Claudin18.2 antigen. The treatment aims to provide a highly targeted approach that may improve outcomes while reducing damage to healthy tissues.
China has emerged as a global leader in the development of Claudin18.2-targeted CAR-T therapies, with several innovative products demonstrating encouraging results in patients with advanced solid tumors, particularly gastric cancer.
What is Claudin18.2?
Claudin18.2 is a tight junction protein normally found in the gastric mucosal lining of the stomach. Under normal conditions, its expression is largely restricted and not readily accessible to circulating immune cells.
During malignant transformation, Claudin18.2 becomes exposed on the surface of tumor cells, making it an ideal target for immunotherapy. Researchers have identified significant Claudin18.2 expression in several cancers, including:
- Gastric cancer
- Gastroesophageal junction (GEJ) cancer
- Pancreatic cancer
- Esophageal adenocarcinoma
- Biliary tract cancer
- Certain ovarian cancers
The presence of Claudin18.2 can be determined through specialized laboratory testing performed on tumor tissue samples. Patients whose tumors express this target may be eligible for Claudin18.2-directed therapies.
How Claudin18.2 CAR-T cell therapy works
Claudin18.2 CAR-T therapy involves collecting a patient’s T cells and genetically modifying them in a laboratory to express a chimeric antigen receptor (CAR) that specifically recognizes Claudin18.2.
The treatment process generally includes:
- Collection of T cells from the patient through leukapheresis
- Genetic engineering of the cells to express Claudin18.2-specific CARs
- Expansion of the modified cells in a specialized manufacturing facility
- Administration of lymphodepleting chemotherapy
- Infusion of the CAR-T cells back into the patient
- Monitoring and follow-up after treatment
Once infused, the engineered T cells circulate throughout the body and identify cancer cells expressing Claudin18.2. Upon recognition, the CAR-T cells become activated and initiate a targeted immune response that destroys the tumor cells.
Additionally, CAR-T cells can expand inside the patient’s body and continue to provide ongoing immune surveillance against cancer recurrence.
Cancers that may benefit from Claudin18.2 CAR-T therapy
Claudin18.2 CAR-T therapy is primarily being developed for gastrointestinal cancers that express the Claudin18.2 antigen.
Potential indications include:
- Advanced gastric cancer
- Gastroesophageal junction cancer
- Metastatic gastric adenocarcinoma
- Pancreatic cancer
- Esophageal adenocarcinoma
- Biliary tract cancers
Many patients being evaluated for Claudin18.2 CAR-T therapy have previously received standard treatments such as surgery, chemotherapy, targeted therapy, immunotherapy, or radiation therapy. The treatment may offer a potential option for patients with relapsed, refractory, or advanced disease.
Clinical progress in China
China has become one of the world’s most active centers for Claudin18.2 CAR-T research and development. Chinese biotechnology companies and medical centers have conducted multiple clinical studies evaluating the safety and effectiveness of this approach.
Several studies have reported encouraging anti-tumor activity in heavily pretreated patients with advanced gastric and gastroesophageal junction cancers. Some patients have achieved significant tumor shrinkage, durable disease control, and prolonged survival.
China has also pioneered the development of next-generation Claudin18.2 CAR-T platforms designed to improve cell persistence, enhance tumor infiltration, and overcome the challenges associated with treating solid tumors.
The rapid growth of China’s cell therapy ecosystem, combined with extensive clinical experience, has positioned the country at the forefront of Claudin18.2 CAR-T innovation.
Advantages of Claudin18.2 CAR-T therapy
Claudin18.2 CAR-T therapy offers several potential advantages compared with traditional treatment approaches.
Potential benefits include:
- Highly targeted recognition of Claudin18.2-positive cancer cells
- Personalized treatment using the patient’s own immune cells
- Potential for durable anti-tumor responses
- Ability to attack cancer cells throughout the body
- Potential effectiveness after failure of standard therapies
- Ongoing immune surveillance through CAR-T cell persistence
- Expanding treatment options for difficult-to-treat solid tumors
While outcomes vary among patients, the therapy represents an important advancement in the pursuit of more effective treatments for gastrointestinal cancers.
Potential side effects
Like other CAR-T therapies, Claudin18.2 CAR-T treatment may be associated with side effects that require careful monitoring and management by experienced medical teams.
Commonly reported side effects include:
- Cytokine release syndrome (CRS)
- Fever
- Fatigue
- Low blood cell counts
- Nausea
- Loss of appetite
- Infection risk
- Gastrointestinal symptoms
Most adverse events can be managed with appropriate supportive care and close medical supervision. Patients undergoing treatment typically receive intensive monitoring during the initial period following infusion.
Patient evaluation and eligibility
Not all patients are suitable candidates for Claudin18.2 CAR-T therapy. A comprehensive evaluation is necessary to determine eligibility.
Factors that may be considered include:
- Confirmation of Claudin18.2 expression
- Cancer type and stage
- Previous treatment history
- Overall health condition
- Organ function
- Performance status
- Presence of active infections or other medical conditions
Specialized testing and consultation with experienced CAR-T specialists are essential before proceeding with treatment.
Future outlook
Claudin18.2 CAR-T cell therapy represents one of the most exciting developments in solid tumor immunotherapy. Ongoing research is focused on improving efficacy, reducing toxicity, and expanding access to a broader range of patients.
Future developments may include:
- Combination therapies with checkpoint inhibitors
- Enhanced CAR-T cell engineering technologies
- Multi-target CAR-T approaches
- Earlier use in treatment pathways
- Expanded indications beyond gastric cancer
- Improved manufacturing processes
As research continues to advance, Claudin18.2 CAR-T therapy has the potential to become an important treatment option for patients with gastrointestinal cancers and other Claudin18.2-positive malignancies.
Claudin18.2 CAR-T therapy in China
China is recognized as a leading destination for Claudin18.2 CAR-T therapy development and clinical application. The country hosts numerous specialized centers with expertise in cellular immunotherapy and advanced cancer treatment.
International patients seeking innovative treatment options may benefit from access to experienced multidisciplinary teams, advanced manufacturing capabilities, and a rapidly evolving ecosystem dedicated to cell-based therapies.
As the field continues to progress, Claudin18.2 CAR-T therapy is expected to play an increasingly important role in the treatment of gastric cancer and other solid tumors worldwide.